High-dose gadolinium-enhanced MR study in the evaluation of central nervous system metastases

This paper reports on the efficacy of higher doses of gadolinium in the evaluation of central nervous system (CNS) metastases. Twenty-three patients with a clinical suspicion of CNS metastases were prospectively studied with 0.1 and 0.3 mmol/kg gadoteridol (ProHance, Squibb Diagnostics), a nonionic, low-osmolality contrast agent. No clinically significant adverse effects were noted. High-dose (0.3 mmol/kg) images provided significant improvement in visualization (70/71) and detection (42 new lesions in 18/23 patients) of lesions. Two patients had no detectable lesions. The additional information gained by high-dose examinations contributed to a potential modification in surgical planning and radiation therapy in 9/23 patients